MBDB


1,3-Benzodioxolyl-N-methylbutanamine is an entactogen of the phenethylamine chemical class. It is known by the street names Eden and Methyl-J. MBDB is a closely related chemical analogue of MDMA, with the only difference between the two molecules being an ethyl group instead of a methyl group attached to the alpha carbon. It has IC50 values of 784 nM against 5-HT, 7825 nM against dopamine, and 1233 nM against norepinephrine. Its metabolism has been described in scientific literature.
MBDB was first synthesized by pharmacologist and medicinal chemist David E. Nichols and later tested by Alexander Shulgin and described in his book, PiHKAL: A Chemical Love Story. MBDB's dosage, according to PiHKAL, is 180–210 mg; the proper dosage relative to body mass seems unknown. Its duration is 4–6 hours, with noticeable after-effects lasting for 1–3 hours.
MBDB was initially developed as a non-psychedelic entactogen. It has lower effects on the dopamine system in comparison to other entactogens such as MDMA. MBDB causes many mild, MDMA-like effects, in particular the lowering of social barriers and inhibitions, pronounced sense of empathy and compassion, mood lift, and mild euphoria, all of which are present. MBDB tends to produce less euphoria, psychedelia, and stimulation in comparison to MDMA.

Legal Status

Unlike MDMA, MBDB is not internationally scheduled under the United Nations Convention on Psychotropic Substances. The thirty-second meeting of the WHO Expert Committee on Drug Dependence evaluated MBDB and recommended against scheduling. From the WHO Expert Committee assessment of MBDB:

Australia

MBDB is considered a Schedule 9 Prohibited substance in Australia under the Poisons Standard. A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.

Russia

MBDB is included into Schedule 1 of the Controlled Substances Act.

Sweden

health ministry :sv:Statens folkhälsoinstitut|Statens folkhälsoinstitut classified MBDB as "health hazard" under the act :sv:Lagen om förbud mot vissa hälsofarliga varor|Lagen om förbud mot vissa hälsofarliga varor as of Feb 25, 1999, in their regulation SFS 1999:58 listed as "2-metylamino-1--butan ", making it illegal to sell or possess.